Hazlett, Burt & Watson’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
F
Hazlett, Burt & Watson's NVO Position: Q2 2026 in Review
Hazlett, Burt & Watson reduced its Novo Nordisk (NVO) stake by 20% in Q2 2026, selling an estimated $83K and leaving 7,889 shares worth $380K. The position accounts for 0.1% of the portfolio, ranked #180.
Hazlett, Burt & Watson first reported a position in NVO in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.39M in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Hazlett, Burt & Watson held 7,889 shares of Novo Nordisk worth $380K as of Q2 2026.
- Hazlett, Burt & Watson sold 1,932 Novo Nordisk shares in Q2 2026, an estimated $83K.
- Novo Nordisk made up 0.1% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #180 holding.
- Hazlett, Burt & Watson first reported a position in Novo Nordisk in Q1 2022 and has held it in 18 quarters since.
- Hazlett, Burt & Watson's Novo Nordisk position peaked at $1.39M in Q2 2024.
- 1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.